EP 3327441 A4 20181219 - METHOD FOR ASSISTING DIAGNOSIS OF CONDITIONS OF MYELOFIBROSIS, METHOD FOR ASSISTING PREDICTION OF PROGNOSIS, METHOD FOR MONITORING THERAPEUTIC EFFECT, AND MARKER AND DEVICE TO BE USED THEREIN
Title (en)
METHOD FOR ASSISTING DIAGNOSIS OF CONDITIONS OF MYELOFIBROSIS, METHOD FOR ASSISTING PREDICTION OF PROGNOSIS, METHOD FOR MONITORING THERAPEUTIC EFFECT, AND MARKER AND DEVICE TO BE USED THEREIN
Title (de)
VERFAHREN ZUR UNTERSTÜTZUNG DER DIAGNOSE VON MYELOFIBROSEERKRANKUNGEN, VERFAHREN ZUR UNTERSTÜTZUNG DER PROGNOSEVORHERSAGE, VERFAHREN ZUR ÜBERWACHUNG DER THERAPEUTISCHEN WIRKUNG SOWIE MARKER UND DARIN ZU VERWENDENDE VORRICHTUNG
Title (fr)
MÉTHODE D'AIDE AU DIAGNOSTIC D'AFFECTIONS DE TYPE MYÉLOFIBROSE, MÉTHODE D'AIDE À LA PRÉDICTION DU PRONOSTIC, MÉTHODE DE SURVEILLANCE D'UN EFFET THÉRAPEUTIQUE, ET MARQUEUR ET DISPOSITIF UTILISÉS POUR CE FAIRE
Publication
Application
Priority
- JP 2015146977 A 20150724
- JP 2016071746 W 20160725
Abstract (en)
[origin: EP3327441A1] The present invention relates to a method for assisting the diagnosis of the condition of myelofibrosis (MF), a method for assisting the prognostic prediction of MF, and a method for monitoring the therapeutic effect on MF. The present invention also relates to an apparatus for executing these methods. Furthermore, the present invention relates to a marker for determining the condition of myelofibrosis.
IPC 8 full level
G01N 33/68 (2006.01); A61K 31/519 (2006.01); A61K 35/14 (2015.01); A61K 35/28 (2015.01); A61K 41/00 (2006.01); A61P 7/00 (2006.01); G01N 33/53 (2006.01); G01N 33/543 (2006.01)
CPC (source: EP US)
A61K 31/519 (2013.01 - EP US); A61K 35/14 (2013.01 - US); A61K 35/28 (2013.01 - US); A61K 41/00 (2013.01 - US); G01N 33/53 (2013.01 - US); G01N 33/543 (2013.01 - US); G01N 33/57407 (2013.01 - EP); G01N 33/57484 (2013.01 - EP); G01N 33/68 (2013.01 - US); G01N 33/6893 (2013.01 - US); G01N 2333/46 (2013.01 - US); G01N 2333/4724 (2013.01 - EP); G01N 2400/00 (2013.01 - EP); G01N 2800/52 (2013.01 - EP US); G01N 2800/7023 (2013.01 - US)
Citation (search report)
- [A] BEDEKOVICS JUDIT ET AL: "Platelet derived growth factor receptor-beta (PDGFR[beta]) expression is limited to activated stromal cells in the bone marrow and shows a strong correlation with the grade of myelofibr", VIRCHOWS ARCHIV, SPRINGER INTERNATIONAL, BERLIN, DE, vol. 463, no. 1, 8 June 2013 (2013-06-08), pages 57 - 65, XP035373167, ISSN: 0945-6317, [retrieved on 20130608], DOI: 10.1007/S00428-013-1434-0
- [A] ATSUSHI KUNO ET AL: "Reconstruction of a robust glycodiagnostic agent supported by multiple lectin-assisted glycan profiling", PROTEOMICS - CLINICAL APPLICATIONS, 1 August 2013 (2013-08-01), DE, pages n/a - n/a, XP055518835, ISSN: 1862-8346, DOI: 10.1002/prca.201300010
- [A] JOHN J O'SHEA ET AL: "Janus kinase inhibitors in autoimmune diseases", ANNALS OF THE RHEUMATIC DISEASES, vol. 72, no. suppl 2, 25 April 2013 (2013-04-25), GB, pages ii111 - ii115, XP055504432, ISSN: 0003-4967, DOI: 10.1136/annrheumdis-2012-202576
- See references of WO 2017018385A1
Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
DOCDB simple family (publication)
EP 3327441 A1 20180530; EP 3327441 A4 20181219; EP 3327441 B1 20210217; CN 108283013 A 20180713; CN 108283013 B 20201030; JP 6799226 B2 20201216; JP WO2017018385 A1 20180524; US 2018156825 A1 20180607; WO 2017018385 A1 20170202
DOCDB simple family (application)
EP 16830490 A 20160725; CN 201680036508 A 20160725; JP 2016071746 W 20160725; JP 2017530862 A 20160725; US 201815878713 A 20180124